

## ASX RELEASE

### DENSE trial using Volpara shows excellent second-round results

#### Highlights:

- **Second-round results of 10-year DENSE breast screening trial published in *Radiology***
- **False-positive rate significantly reduced relative to initial DENSE results published in December 2019**

Wellington, NZ, 18 March 2021: Volpara Health Technologies (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a health technology software company whose integrated breast care platform assists in the delivery of personalised breast care, announced today the publication of the results of the second round of Project DENSE.

The DENSE trial, based in the Netherlands, started collecting patients 10 years ago and is the first randomised controlled study on the clinical utility of breast MRI supplemental screening for women with extremely dense breasts. The study used Volpara®Density™ software to assess breast density.

The first results from DENSE, released in December 2019, showed a significant reduction in interval cancers in those women being selected for breast MRI using VolparaDensity, but with a relatively high false-positive rate.

These current results cover the incidence (or second) round of Project DENSE, involving over 3,000 women, and show that the false-positive rate has been significantly reduced. Though the incremental cancer detection rate was lower than that of the first round, as expected for the incidence round (5.8 versus 16.5 per 1000 screening examinations), the false-positive rate was only 26.3 versus 79.8 per 1000 screening examinations.

Volpara CEO Dr Ralph Highnam said of the trial: “The first results from DENSE showed a dramatic decrease in the number of interval cancers by varying screening based upon VolparaDensity. These follow-up results demonstrate that as screening programs settle into these new protocols, the number of false positives is significantly reduced and makes the

new protocol much more viable. We are incredibly proud to be part of this work, which has been a 10-year journey for us and the investigators but is showing a real benefit to women.”

### **Authorisation & Additional Information**

This announcement was authorised by the Group CEO of Volpara Health Technologies Limited.

### **ENDS**

### **For further information, please contact:**

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparahealth.com](mailto:ralph.highnam@volparahealth.com)  
t: +64 21 149 0541

Trevor Chappell  
WE Communications  
[WE-AUVolpara@we-worldwide.com](mailto:WE-AUVolpara@we-worldwide.com)  
t: +61 407 933 437

### **About Volpara Health Technologies Limited (ASX: VHT)**

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020. VHT is based in Wellington, New Zealand.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)